MiNK Therapeutics, Inc. (INKT): debt financing — MiNK Therapeutics issues up to $5.0M convertible promissory note to Agenus at 2% interest

MiNK Therapeutics, Inc.

Principal amount up to $5.0M; interest rate 2% per annum, accruing but payable upon conversion or maturity.
Demand repayment on or after Jan 1, 2026; optional conversion into equity upon qualified financing at Agenus's election.
Funds may be drawn in increments with Agenus's consent; advances may include payments made by Agenus on Company's behalf.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

MiNK Therapeutics, Inc. incurred convertible notes of up to $5.0 million with Agenus Inc. at 2% maturing on or after January 1, 2026.

Instrument: convertible notes
Principal: up to $5.0 million
Counterparty: Agenus Inc.
Rate: 2%
Maturity: on or after January 1, 2026
Event: incurrence

Exact text from the filing

On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MiNK Therapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Agenus Inc. valued at $5.0 million (effective 2024-02-12).

Action: entry
Agreement: notes offering
Counterparty: Agenus Inc.
Value: $5.0 million
Effective: 2024-02-12

Exact text from the filing

On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).

View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-014944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.